Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer

Oncology Letters

Volumn 11, Issue 4, 2016, Pages 2605-2610

  Zhang, Lihong ^a,b   Yang, Xuejing ^b,c   Sun, Zhen ^b,c   Li, Jiali ^b   Zhu, Hui ^b   Li, Jing ^b   Pang, Yan ^b  

^a NANKAI UNIVERSITY   (China)

^b Tianjin Union Medicine Centre   (China)

^c Shanghai Claison Biotechnology Co Ltd   (China)

Author keywords

Cytokine induced killer cells; Dendritic cell vaccine; Immunotherapy; Non small cell lung cancer

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR NECROSIS FACTOR;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DELAYED HYPERSENSITIVITY; ERYTHEMA; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; QUALITY OF LIFE; RASH; SQUAMOUS CELL CARCINOMA;

EID: 84960438772     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4273     Document Type: Article

References (37)

1. Gupta N, Hatoum H and Dy GK: First line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxel. Int J Nanomedicine 9: 209-221, 2014.
2. Zhong R, Han B and Zhong H: A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 35: 987-994, 2014.
3. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 5 (Suppl 4): S389-S396, 2013.
4. Hirsh V: Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. World J Clin Oncol 2: 262-271, 2011.
5. Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R and Topolcan O: Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Anticancer Res 36: 461-466, 2016.
6. Choi MK, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, et al: Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Cancer Chemother Pharmacol 73: 1217-1225, 2014.
7. Yang L, Ren B, Li H, Yu J, Cao S, Hao X and Ren X: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62: 65-73, 2013.
8. Kelly RJ, Gulley JL and Giaccone G: Targeting the immune system in non-small-cell lung cancer: Bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer 11: 228-237, 2010.
9. Aktipis CA and Nesse RM: Evolutionary foundations for cancer biology. Evol Appl 6: 144-159, 2013.
10. Schürch CM, Riether C and Ochsenbein AF: Dendritic cell-based immunotherapy for myeloid leukemias. Front Immunol 4: 496, 2013.
11. Liu H, Song J, Yang Z and Zhang X: Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med 6: 953-956, 2013.
12. Linn YC and Hui KM: Cytokine-induced NK-like T cells: From bench to bedside. J Biomed Biotechnol 2010: 435745, 2010.
13. Ma YJ, He M, Han JA, Yang L and Ji XY: A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand J Immunol 78: 387-393, 2013.
14. Sangha R, Price J and Butts CA: Adjuvant therapy in non-small cell lung cancer: Current and future directions. Oncologist 15: 862-872, 2010.
15. Severo M, Gaio R, Lourenço P, Alvelos M, Bettencourt P and Azevedo A: Indirect calibration between clinical observers-application to the New York Heart Association functional classification system. BMC Res Notes 4: 276, 2011.
16. Ribeiro JP, Matuguma SE, Cheng S, Herman P, Sakai P, D’Albuquerque LA and Maluf-Filho F: Results of treatment of esophageal variceal hemorrhage with endoscopic injection of n-butyl-2-cyanoacrylate in patients with Child-Pugh class C cirrhosis. Endosc Int Open 3: E584-E589, 2015.
17. Li Y, Yin J, Li T, Huang S, Yan H, Leavenworth J and Wang X: NK cell-based cancer immunotherapy: From basic biology to clinical application. Sci China Life Sci 58: 1233-1245, 2015.
18. Dai H, Wang Y, Lu X and Han W: Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst 108: djv439, 2016.
19. Yu D, Du K, Liu T and Chen G: Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients. Int J Mol Sci 14: 11145-11156, 2013.
20. Wang R, Wang G, Zhang N, Li X and Liu Y: Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer. Biomed Res Int 2013: 195692, 2013.
21. Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, et al: CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: Results of a meta-analysis in 2063 patients. Br J Cancer 90: 2097-2105, 2004.
22. Cui Y, Yang X, Zhu W, Li J, Wu X and Pang Y: Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett 6: 537-541, 2013.
23. Mitchell DA and Sampson JH: Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics 6: 527-538, 2009.
24. Liu Y, Zhang W, Zhang B, Yin X and Pang Y: DC vaccine therapy combined concurrently with oral capecitabine in metastatic colorectal cancer patients. Hepatogastroenterology 60: 23-27, 2013.
25. Wang M, Shi SB, Qi JL, Tang XY and Tian J: S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Med Oncol 30: 747, 2013.
26. Sabado RL and Bhardwaj N: Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2: 37-56, 2010.
27. Mantia-Smaldone GM, Corr B and Chu CS: Immunotherapy in ovarian cancer. Hum Vaccin Immunother 8: 1179-1191, 2012.
28. Minidis NM, Mesner O, Agan BK and Okulicz JF: Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy. J Int AIDS Soc 17: 18799, 2014.
29. Timmermann C: ‘Just give me the best quality of life questionnaire’: The Karnofsky scale and the history of quality of life measurements in cancer trials. Chronic Illn 9: 179-190, 2013.
30. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L and Wolchok J: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102: 1388-1397, 2010.
31. Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi R and Barone C: The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol 2011: 894704, 2011.
32. Yuanying Y, Lizhi N, Feng M, Xiaohua W, Jianying Z, Fei Y, Feng J, Lihua H, Jibing C, Jialiang L and Kecheng X: Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology 67: 235-240, 2013.
33. Ma X, Lin C and Zhen W: Cancer care in China: A general review. Biomed Imaging Interv J 4: e39, 2008.
34. Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature 480: 480-489, 2011.
35. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P and Ferrone S: Immunotherapy of cancer in 2012. CA Cancer J Clin 62: 309-335, 2012.
36. Thomas AA, Ernstoff MS and Fadul CE: Immunotherapy for the treatment of glioblastoma. Cancer J 18: 59-68, 2012.
37. Maggi E: T-cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol 161: 10-18, 2010.